Photo taken from UroToday/X
Jun 24, 2024, 01:48
Novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer
UroToday shared a post on X: .
“The EvoPAR-Prostate 01 Trial: Novel PARP inhibitor saruparib in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Neeraj Agarwal from Huntsman Cancer Institute and Zach Klaassen from Georgia Cancer Center discuss this new PARP inhibitor combined with ARPI in both biomarker-positive and negative populations.”
Proceed to the video.
Source: UroToday/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 09:38
Oct 22, 2024, 08:02
Oct 22, 2024, 07:20
Oct 22, 2024, 06:30
Oct 22, 2024, 06:13
Oct 22, 2024, 04:01
Oct 22, 2024, 03:40
Oct 22, 2024, 00:56
Oct 22, 2024, 00:49
Oct 22, 2024, 00:40